The Key Players in The Generic Drugs Market in Japan 2015-2019

Friday 24 April 2015, Amsterdam

The report recognizes the following companies as the key players in the Generic Drugs Market in Japan: Meiji Seika Pharma Co. Ltd., Nichi-Iko Pharmaceutical Co. Ltd., Nipro Pharma Corp., Sawai Pharmaceuticals Co. Ltd., Teva Pharmaceutical Industries Ltd. and Towa Pharmaceutical Co. Ltd.

Other Prominent Vendors in the market are: Actavis, Daiichi Sankyo, Daito Pharmaceutical, Eisai, Fuji Pharma, GlaxoSmithKline, Hikari Pharmaceutical, Hospira, Mylan, Nihon Generic, Nippon Chemipher, Nippon Kayaku, Nissin Pharmaceutical, Ohara Pharmaceutical, Pfizer, Sandoz, Taiyo Yakuhin, Takeda Pharmaceutical and Zensei Pharmaceutical Industries.

The report said: “Increased initiatives by government and healthcare service providers are one of the major trends emerging in the market. Doctors and pharmacists are encouraged to use generics and reassure patients of their quality and efficacy.”

According to the report, the patents of many first-generation approved biopharmaceuticals are set to expire within the forecast period, leading to competition from generic drugs. As a result of the economic crisis, the development of new drugs has been hindered. Major companies in the market have allocated minimal funds for the R&D of innovative drugs. This has led to the drying up of pipeline drugs, paving the way for the Generic Drugs market.

Further, the report states that intense competition among vendors is one of the primary challenges, leading to a decrease in profit margins and an increase in pricing pressure. As a result of the intense competition, leading vendors are currently operating on low-profit margins with severe pressure on pricing strategies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.